Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
Università Cattolica del Sacro Cuore, Milan, Italy.
Adv Tech Stand Neurosurg. 2023;48:123-137. doi: 10.1007/978-3-031-36785-4_6.
Pediatric optic pathway gliomas (OPG) are low-grade brain tumors characterized by slow progression and invalidating visual loss. Common therapeutic strategies include surgery, radiotherapy, chemotherapy, and combinations of these modalities, but despite the different treatment strategies, no actual treatment exists to prevent or revert visual impairment. Nowadays, several reports of the literature show promising results regarding NGF eye drop instillation and improvement of visual outcome. Such results seem to be related with the NGF-linked prevention in caspase activation, which reduces retinal ganglion cell loss.Reducing retinal ganglion cell loss results clinically in visual field improvement as well as visual electric potential and optical coherence tomography gain. Nonetheless, visual acuity fails to show significant changes.Visual impairment represents nowadays one of the major issues in dealing with OPGs. Secondary to the interesting results offered by NGF eye drop administration, further studies are warranted to better comprehend potential treatment strategies.
小儿视神经胶质瘤（OPG）是一种低级别脑肿瘤，其特点是进展缓慢，导致视力丧失。常见的治疗策略包括手术、放疗、化疗以及这些方法的联合应用，但尽管有不同的治疗策略，目前还没有实际的治疗方法可以预防或逆转视力损害。目前，一些文献报道显示，NGF 滴眼剂滴眼在改善视觉预后方面有很好的效果。这些结果似乎与 NGF 相关的 caspase 激活预防有关，可减少视网膜神经节细胞的丢失。减少视网膜神经节细胞的丢失可导致视野改善以及视觉电生理和光学相干断层扫描的增益。然而，视力却没有明显的改善。视力损害是目前小儿视神经胶质瘤治疗的主要问题之一。鉴于 NGF 滴眼剂给药带来的有趣结果，有必要进行进一步的研究以更好地了解潜在的治疗策略。
